LONDON, February 1, 2012 /PRNewswire/ --
Cynosure are one of the leading global aesthetic laser manufacturers, and the mastermind behind the original SmartLipo laser. In September 2011, the UK arm launched Cellulaze - for the long term removal of cellulite.
"Cellulaze is the world's first surgical treatment for cellulite designed to treat women who have struggled to eliminate cellulite through diet and exercise," said Cynosure President and Chief Executive Officer Michael Davin.
Unlike temporary, non-invasive treatments on the market, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, with clinically proven results. In the US alone, patient trials have demonstrated that after 2 years post-procedure no cellulite has returned on the areas treated.
Neil Wolfenden, Cynosure UK Managing Director, said:
"We have been extremely fortunate that in Europe the Cellulaze laser treatment has CE mark approval prior to the awaiting FDA approval. To-date we have witnessed high patient satisfaction across the board, and impressive national press coverage.
"The recent FDA approval now provides extra peace of mind and assurance to the UK surgeons and patients that Celllulaze is now a global phenomenon in aesthetic surgery."
Nearly four years of clinical research puts Cellulaze in a class of its own: the only single-treatment aesthetic procedure clinically shown to reduce cellulite. Clinical data has demonstrated that Cellulaze treatments can increase the thickness of the skin by 25% and increase the elasticity of the skin by 29% at one year. No other anti-cellulite treatment has been proven to deliver these results.
For more info on this revolutionary new treatment visit:
SOURCE Cynosure UK